Immunovia presents data from discovery study at 2024 PancreasFest medical conference
PancreasFest is an annual conference of physicians and translational researchers with special interest in the pancreas who convene to find new ways to improve the care of patients with pancreatic disease, including pancreatic cancer. It is organized by the
Results presented at PancreasFest reflect a detailed scientific presentation of the initial positive data the company shared in a
The discovery study, the most comprehensive pancreatic cancer proteomics study done to date, identified 15 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC). These protein biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. Over 3,000 proteins were evaluated in 329 blood samples from Stage 1 and II PDAC and non-PDAC matched control patients using
"We are honored to have been chosen to present the discovery study results at this important conference. We look forward to discussing the detailed study data and receiving scientific and clinical insights from this key group of physicians and researchers who are experts in pancreatic cancer," said Norma Palma PhD, Vice President of Clinical and Medical Affairs at
For more information, please contact:
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
CONTACT:
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.co.uk/news-releases/immunovia-presents-data-from-discovery-study-at-2024-pancreasfest-medical-conference-302206926.html